Nintedanib appears to have a similar protective effect on podocyte loss in FSGS relapse plasma to that observed with TGFβ1/Adriamycin conditions (Fig. 6 vs Fig. 7). Here, TGFB1 is linked to focal segmental glomerulosclerosis.